Company news

PDS Biotechnology Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine

December 20, 2020

PDS Biotechnology Appoints Seth Van Voorhees as Chief Financial Officer

December 8, 2020

PDS Biotech Announces New and Broad Versamune® Platform Patent Claims

November 15, 2020

PDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update

November 10, 2020

PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine

November 9, 2020

PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent/Metastatic Head and Neck Cancer in Collaboration with Merck

November 8, 2020

PDS Biotechnology Appoints Renowned Oncologist Otis Brawley, M.D. to its Board of Directors

November 4, 2020

PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 in Combination with Standard of Care Chemoradiotherapy in Advanced Cervical Cancer

October 25, 2020

PDS Biotechnology Corporation Announces Closing of Approx. $19 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

August 12, 2020

PDS Biotechnology Corporation Announces Pricing of $16.5 Million Public Offering of Common Stock

August 10, 2020

PDS Biotechnology Corporation Announces Proposed Public Offering of Common Stock

August 9, 2020

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2020 Financial Results

July 29, 2020

PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19

July 26, 2020

PDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune®-Based Universal Influenza Vaccine

July 13, 2020

PDS Biotechnology and Farmacore Biotechnology Announce Co-Development of PDS0204 COVID-19 Vaccine

June 16, 2020

PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute

June 14, 2020

PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Cancer

June 3, 2020

PDS Biotechnology Announces Publication at American Society of Clinical Oncology (ASCO) 2020

May 12, 2020

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2020 Financial Results

May 3, 2020

PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune®-Based Anti-Cancer Product

April 28, 2020

PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial

April 15, 2020

PDS Biotechnology Appoints Dr. Ilian Iliev to Board of Directors

April 8, 2020

PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update

March 26, 2020

PDS Biotechnology Announces Resignation of Andrew Saik as CFO

March 22, 2020

PDS Biotechnology Expands Patent Portfolio for its Novel Versamune® Platform

March 4, 2020

PDS Biotechnology Announces Commencement of Work Under a Pre-Clinical Collaboration with Farmacore Biotechnology for Tuberculosis

February 26, 2020

PDS Biotechnology Appoints Kamil Ali-Jackson, Esq. to Board of Directors

February 23, 2020

PDS Biotechnology Corporation Announces Closing of Public Offering

February 13, 2020

PDS Biotechnology Corporation Announces Pricing of Public Offering of Approximately $12 Million of Shares of Common Stock

February 10, 2020

PDS Biotechnology Announces Principal Investigator and Independent Data Monitoring Committee for its Phase 2 Clinical Collaboration with Merck

December 10, 2019

PDS Biotechnology Reports Third Quarter 2019 Financial Results and Provides Business Update

November 6, 2019

PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101

October 21, 2019

PDS Biotechnology Corp. Announces Clinical Collaboration with Merck

October 2, 2019

PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial

September 18, 2019

← Newer news releases

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 75 decks. Every deck is listed under its year.